In the PRATO-ACS trial , @ consecutive statin-nave non-ST-elevation acute coronary syndrome patients scheduled for early invasive strategy and pretreated with high-dose clopidogrel were randomly assigned to rosuvastatin ( @ mg on admission followed by @ mg/d ; statin group , n = @ ) or no statin treatment ( control group , n = @ ) .